| Project/Area Number |
07457082
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
SATAKE Masanobu Institute of Development, Aging and Cancer, Tohoku University, Professor, 加齢医学研究所, 教授 (50178688)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NIKI Masaru Institute of Development, Aging and Cancer, Tohoku University, Instructor, 加齢医学研究所, 助手 (60241626)
|
|---|
| Project Period (FY) |
1995 – 1996
|
| Project Status |
Completed (Fiscal Year 1996)
|
| Budget Amount *help |
¥7,000,000 (Direct Cost: ¥7,000,000)
Fiscal Year 1996: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1995: ¥5,700,000 (Direct Cost: ¥5,700,000)
|
|---|
| Keywords | transcription factor / Tlymphocyte / hematopoietic stem cell / gene targeting / PEBP2 |
|---|
| Research Abstract |
The Pebpb2 gene encodes a non-DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF and is rearranged in inversion of chromosome 16 associated with human acute myeloid leukemia. To investigate its physiological function, Pebpb2 was mutated by a targeting strategy to generate a null mutant. The homozygous mutation in mice proved lethal in embryos around E12.5, apparently due to massive hemorrhaging in the central nervous system. In addition, definitive hematopoiesis in the liver was severely impaired. The observed phenotype was indistinguishable from that reported for homozygous disruption of AML1, which encodes a DNA binding subunit of PEBP2/CBF.Thus, the results indicate that the two subunits function together as a heterodimeric PEBP2/CBF in vivo and that PEBP2/CBF plays an essential role in development of definitive hematopoiesis.
|
